Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00025233 · OUTCOME

Performance Status

Bevacizumab in Treating Patients With Persistent or Recurrent Cancer of the Cervix · Source last updated 2019-07-24

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
Baseline

What was measured

Performance Status 0 = Fully active, able to carry on all pre-disease performance without restriction Performance Status 1 = Restricted in physically strenuous activity but ambulatory and able to carry out work of light or sedentary nature, e.g., light housework, office work Performance Status 2 = Ambulatory and capable of all self care but unable to carry out any work activities. Up and about more than 50% of waking hours.

Analysis population: Eligible and treated patients.

Groups in this outcome

Bevacizumab

Bevacizumab 15 mg/kg IV, every 3 weeks (one cycle) until disease progression or adverse effects prohibit further therapy

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Bevacizumab46

Reported measurements

Source class 1

Performance Status 0

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Bevacizumab22Not reportedNot reportedNot reportedNot reported

Performance Status 1

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Bevacizumab23Not reportedNot reportedNot reportedNot reported

Performance Status 2

Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Bevacizumab1Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        22
      title
      Performance Status 0
    2. measurements
      1. group Id
        OG000
        value
        23
      title
      Performance Status 1
    3. measurements
      1. group Id
        OG000
        value
        1
      title
      Performance Status 2
denoms
  1. counts
    1. group Id
      OG000
      value
      46
    units
    Participants
description
Performance Status 0 = Fully active, able to carry on all pre-disease performance without restriction Performance Status 1 = Restricted in physically strenuous activity but ambulatory and able to carry out work of light or sedentary nature, e.g., light housework, office work Performance Status 2 = Ambulatory and capable of all self care but unable to carry out any work activities. Up and about more than 50% of waking hours.
groups
  1. description
    Bevacizumab 15 mg/kg IV, every 3 weeks (one cycle) until disease progression or adverse effects prohibit further therapy
    id
    OG000
    title
    Bevacizumab
param Type
COUNT_OF_PARTICIPANTS
population Description
Eligible and treated patients.
reporting Status
POSTED
time Frame
Baseline
title
Performance Status
type
SECONDARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice